ArticleThe Journal of clinical investigation2021

Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model.

Melody Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.